Search

Your search keyword '"Comito F"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Comito F" Remove constraint Author: "Comito F"
65 results on '"Comito F"'

Search Results

1. Prevalence and predictive role of hypertriglyceridemia in statin-treated patients at very high risk: Insights from the START study

2. Prevalence and predictive role of hypertriglyceridemia in statin-treated patients at very high risk: insights from the START Study

3. COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry

4. COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry

5. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis

6. Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study

8. Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution.

9. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

10. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial

11. Regular Wine Consumption in Chronic Heart Failure: Impact on Outcomes, Quality of Life, and Circulating Biomarkers

17. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

19. [Predictive value of various echocardiographic parameters of systolic and diastolic function in the development of congestive heart failure after infarction]

22. Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer

23. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience

24. Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab

25. Non-coding RNA dysregulation in skin cancers

26. Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis

27. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial

28. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

29. Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

30. Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.

31. Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.

33. Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study.

34. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.

38. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.

40. Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.

41. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.

42. Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer.

43. Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma.

44. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.

45. Non-coding RNA dysregulation in skin cancers.

46. Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab.

47. Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.

48. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.

49. Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.

50. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Catalog

Books, media, physical & digital resources